Review of TA181; Pemetrexed for the first-line treatment of non-small-cell lung cancer, TA190; Pemetrexed for the maintenance treatment of non-small-cell lung cancer, TA192; Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer, TA227; Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer, and TA258; Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

The Institute was proposing the guidance in all 5 appraisals should be transferred to the ‘static guidance list’, and that TA192 and TA258 should be flagged for further consideration of a review when the results of the LUX Lung 7 trial are available, currently anticipated to be in 2015.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

As a result, TA181, TA190, TA192, TA227 and TA258 will all be moved to the ‘static guidance list’.  TA192 and TA258 should be flagged for further consideration of a review when the results of the LUX Lung 7 trial are available, currently anticipated to be in 2015.  Additionally, should the clinical guideline for lung cancer (CG1    21) be updated, then these appraisals will be re-considered for review and removal from the static list.

December 2014